234 related articles for article (PubMed ID: 37063900)
1. Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment.
Hess NJ; Kink JA; Hematti P
Front Immunol; 2023; 14():1143381. PubMed ID: 37063900
[TBL] [Abstract][Full Text] [Related]
2. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
[TBL] [Abstract][Full Text] [Related]
3. Early myeloid-derived suppressor cells (HLA-DR
Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
Front Immunol; 2020; 11():989. PubMed ID: 32528476
[TBL] [Abstract][Full Text] [Related]
5. Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
Oshrine B; Innamarato P; Branthoover H; Nagle L; Verdugo P; Pilon-Thomas S; Beatty M
Transplant Cell Ther; 2022 Apr; 28(4):203.e1-203.e7. PubMed ID: 34995816
[TBL] [Abstract][Full Text] [Related]
6. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
[TBL] [Abstract][Full Text] [Related]
7. Graft-Versus-Host Disease Prevention by
Scheurer J; Kitt K; Huber HJ; Fundel-Clemens K; Pflanz S; Debatin KM; Strauss G
Front Immunol; 2021; 12():754316. PubMed ID: 34721430
[TBL] [Abstract][Full Text] [Related]
8. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
[TBL] [Abstract][Full Text] [Related]
10. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
[TBL] [Abstract][Full Text] [Related]
11. Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation.
Koehn BH; Blazar BR
J Leukoc Biol; 2017 Aug; 102(2):335-341. PubMed ID: 28148718
[TBL] [Abstract][Full Text] [Related]
12. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
13. The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).
Demosthenous C; Sakellari I; Douka V; Papayanni PG; Anagnostopoulos A; Gavriilaki E
J Clin Med; 2021 May; 10(10):. PubMed ID: 34064671
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway.
Zhang B; Yeo RWY; Lai RC; Sim EWK; Chin KC; Lim SK
Cytotherapy; 2018 May; 20(5):687-696. PubMed ID: 29622483
[TBL] [Abstract][Full Text] [Related]
16. Can we prevent or treat graft-versus-host disease with cellular-therapy?
Zahid MF; Lazarus HM; Ringdén O; Barrett JA; Gale RP; Hashmi SK
Blood Rev; 2020 Sep; 43():100669. PubMed ID: 32089398
[TBL] [Abstract][Full Text] [Related]
17. Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses.
Bolivar-Wagers S; Loschi ML; Jin S; Thangavelu G; Larson JH; McDonald-Hyman CS; Aguilar EG; Saha A; Koehn BH; Hefazi M; Osborn MJ; Jensen MC; Wagner JE; Pennell CA; Blazar BR
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35917188
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
19. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
[TBL] [Abstract][Full Text] [Related]
20. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
